Biovision is a pioneering biotech company that is at the forefront of gene therapy advancements. With a focus on immune cells, particularly genetically engineered B cells, Biovision is on a mission to revolutionize the treatment of rare diseases. These B cells are responsible for producing antibodies in our bodies and have the potential to be harnessed for gene therapy.

Biovision's groundbreaking approach involves engineering B cells to produce specific proteins instead of antibodies. By doing so, they aim to address the absence of crucial enzymes that result in severe symptoms of diseases like MPS-1, a rare inherited disorder. With the approval from the US Food and Drug Administration, Biovision is thrilled to announce that they are the first to enter clinical trials for this innovative gene therapy.

Led by CEO Sean Ainsworth, Biovision is committed to making significant strides in the field of gene therapy. Their cutting-edge research and dedication to improving lives set them apart as leaders in the biotechnology industry. With Biovision's pioneering work, a brighter future is on the horizon for patients suffering from rare genetic diseases